Carfimib 60mg Injection

About

Carfimib 60mg Injection is a potent and selective proteasome inhibitor, primarily indicated for the treatment of multiple myeloma. This medication works by irreversibly binding to and inhibiting the chymotrypsin-like activity of the 20S proteasome, a crucial enzyme complex involved in protein degradation within cells. By disrupting this process, Carfimib leads to an accumulation of misfolded and ubiquitinated proteins, triggering endoplasmic reticulum stress and ultimately inducing apoptosis in cancer cells. It is typically administered intravenously and is often used in patients who have experienced disease progression after prior therapies, or as part of a combination regimen for newly diagnosed patients. Its targeted action helps to control disease progression and improve patient outcomes in this challenging hematological malignancy.

Uses

• Treatment of relapsed or refractory multiple myeloma.
• Used in combination with other agents for multiple myeloma.
• Management of newly diagnosed multiple myeloma.
• Part of a treatment regimen for specific blood cancers.

Directions For Use

Administered intravenously by a healthcare professional. Dosage and frequency are determined by your doctor.

Benefits

• Effective in relapsed/refractory multiple myeloma.
• Improves progression-free survival.
• Can be used in combination therapies.
• Targeted mechanism of action.
• Helps overcome treatment resistance.
• Contributes to disease control.

Side Effects

• Thrombocytopenia (low platelet count)
• Anemia
• Neutropenia (low white blood cell count)
• Fatigue
• Nausea
• Diarrhea
• Dyspnea (shortness of breath)
• Hypertension (high blood pressure)
• Peripheral neuropathy
• Pyrexia (fever)
• Headache
• Cough

Safety Measures

• Alcohol - Avoid alcohol during treatment as it may exacerbate gastrointestinal side effects and increase liver strain.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if the drug is excreted in human milk and could harm the infant.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary, and liver function should be monitored.
• Kidney - Use with caution in patients with renal impairment. Dose adjustments may be required based on creatinine clearance.
• Lung - Monitor for pulmonary hypertension and dyspnea. Patients with pre-existing lung conditions should be closely observed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.